MRI检查对MSS/pMMR型局部进展期直肠癌抗PD‑1联合新辅助治疗效果的评估价值

Application value of MRI in evaluating the efficacy of anti‑PD‑1 combined with neoadjuvant therapy for microsatellite stability/proficient mismatch repair locally advanced rectal cancer

  • 摘要:
    目的 探讨磁共振成像(MRI)检查对微卫星稳定(MSS)/错配修复蛋白表达完整(pMMR)型局部进展期直肠癌抗程序性死亡受体1(PD‑1)联合新辅助治疗效果的评估价值。
    方法 采用前瞻性单臂Ⅱ期研究方法。选取2021年4月至2022年9月首都医科大学附属北京友谊医院收治的37例MSS/pMMR型局部进展期直肠癌患者的临床病理资料。患者均行抗PD‑1联合新辅助治疗和全直肠系膜切除根治术。观察指标:(1)入组患者情况。(2)患者MRI及病理学检查情况。(3)MRI检查阅片的一致性分析。(4)MRI检查评估情况。正态分布的计量资料以x±s表示。计数资料以绝对数或百分比表示。采用线性加权κ值评价放射科医师评估的一致性。采用灵敏度、阴性预测值、准确率、分期过高率和分期不足率评价预测价值。
    结果 (1)入组患者情况。筛选出符合条件的患者37例;男21例,女16例;年龄为(61±11)岁。患者联合治疗前后分别行MRI检查,根治术后行病理学检查。(2)患者MRI及病理学检查情况。37例患者中,联合治疗前MRI检查结果显示:T0期、T1期、T2期、T3期、T4期分别为0、0、5、24、8例,N0期、N1期、N2期分别为10、17、10例,壁外血管侵犯(EMVI)阳性、阴性分别为28、9例,系膜筋膜阳性、阴性分别为4、33例;联合治疗后MRI检查结果显示:T0期、T1期、T2期、T3期、T4期分别为15、4、7、10、1例,N0期、N1期、N2期分别为34、2、1例,EMVI阳性、阴性分别为9、28例,系膜筋膜阳性、阴性分别为1、36例。MRI检查肿瘤退缩分级(TRG)0级、1级、2级、3级分别为16、13、8、0例。术后病理学检查结果显示:T0期、T1期、T2期、T3期、T4期分别为18、4、3、11、1例,N0期、N1期、N2期分别为33、3、1例,EMVI阳性、阴性、未知分别为1、35、1例,环周切缘阳性、阴性分别为0、37例,美国癌症联合委员会标准TRG 0级、1级、2级、3级分别为18、9、8、2例;病理学完全缓解率为48.6%(18/37),接近病理学完全缓解率为24.3%(9/37)。(3)MRI检查阅片的一致性分析。联合治疗前MRI检查T分期和N分期的κ值分别为0.839(P<0.05)和0.838(P<0.05);联合治疗后MRI检查T分期和N分期的κ值分别为0.531(P<0.05)和0.846(P<0.05);联合治疗前、后EMVI和系膜筋膜的κ值分别为0.708(P<0.05)、0.561(P<0.05)和0.680(P<0.05)、1.000(P<0.05);TRG 3轮阅片的κ值为0.448(P<0.05)。(4)MRI检查评估情况。①MRI检查评估T、N分期情况:联合治疗后MRI检查评估T0期的准确率为75.7%28/37,95%可信区间(CI)为62.2%~89.2%、分期不足率为8.1%(3/37,95%CI为0~18.9%)、分期过高率为16.2%(6/37,95%CI为5.4%~29.7%),评估T0~2期的准确率为86.5%(32/37,95%CI为73.0%~97.3%)、分期不足率为8.1%(3/37,95%CI为0~18.9%)、分期过高率为5.4%(2/37,95%CI为0~13.5%);评估N分期的准确率为91.9%(34/37,95%CI为81.1%~100.0%)、分期不足率为5.4%(2/37,95%CI为0~13.5%)、分期过高率为2.7%(1/37,95%CI为0~8.1%)。18例病理学T0期患者中,MRI检查分期过高占比为33.3%(6/18);4例病理学T1期患者和3例病理学T2期患者均诊断准确;12例病理学T3~T4期患者中,3例分期不足。37例病理学N0~N2期患者中,34例诊断准确,1例分期过高患者因直肠系膜淋巴结短径6 mm呈圆形而分期为N1期,2例分期不足患者因淋巴结小(最大短径为3 mm)而分期为N0期。②MRI检查评估EMVI和系膜筋膜情况:MRI检查评估EMVI的准确率、灵敏度、阴性预测值分别为86.5%(32/37,95%CI为75.0%~97.2%)、100.0%、100.0%。EMVI高估率为13.9%(5/36,95%CI为2.8%~25.0%),无低估情况。35例病理学检查EMVI阴性患者中,14.3%(5/35)患者MRI检查评估为阳性,分期过高的原因是直肠壁外增厚的纤维组织被误认为是血管侵犯。MRI检查评估系膜筋膜准确率为97.3%(36/37,95%CI为91.9%~100.0%),1例2.7%(1/37),95%CI为0~8.1%因直肠系膜筋膜旁淋巴结被误诊为阳性而高估为系膜筋膜受累;MRI检查评估系膜筋膜的阴性预测值为100.0%。③MRI检查评估TRG情况:MRI检查评估TRG 0级的准确率、分期不足率、分期过高率分别为78.4%(29/37,95%CI为64.9%~91.9%)、8.1%(3/37,95%CI为0~18.9%)、13.5%(5/37,95%CI为5.4%~27.0%);评估TRG 0~1级的准确率、分期不足率、分期过高率分别为89.2%(33/37,95%CI为78.4%~97.3%)、8.1%(3/37,95%CI为0~18.9%)、2.7%(1/37,95%CI为0~8.1%)。18例pCR患者中,5例MRI检查为TRG 1级,13例为TRG 0级。1例接近pCR患者MRI检查为TRG 2级。2例病理学TRG 3级患者MRI检查均未正确诊断。
    结论 抗PD⁃1联合新辅助治疗可有效降低MSS/pMMR型局部进展期直肠癌患者的肿瘤分期;MRI检查对T分期、N分期、EMVI、系膜筋膜和TRG的预测效果较好,但应注意防止过度分期。

     

    Abstract:
    Objective To investigate the application value of magnetic resonance imaging(MRI) in evaluating the efficacy of anti‑PD‑1 combined with neoadjuvant therapy for microsatellite stability (MSS)/proficient mismatch repair (pMMR) locally advanced rectal cancer (LARC).
    Methods The prospective single‑arm phase Ⅱ study was conducted. The clinicopathological data of 37 patients with MSS/pMMR LARC who were admitted to Beijing Friendship Hospital of Capital Medical University from April 2021 to September 2022 were collected. All patients underwent anti‑PD‑1 combined with neoadjuvant therapy and radical total mesorectal excision. Observation indicators: (1) enrolled pati-ents; (2) MRI and pathological examination; (3) concordance analysis of MRI examination reading; (4) evaluation of MRI examination. Measurement data with normal distribution were represented as Mean±SD. Count data were expressed as absolute numbers or percentages. Linear weighted κ value was used to evaluate the concordance of radiologist assessment. Sensitivity, negative predictive value, accuracy, overstaging rate and understaging rate were used to evaluate the predictive value.
    Results (1) Enrolled patients. A total of 37 eligible patients were screened out, including 21 males and 16 females, aged (61±11)years. MRI examination was performed before and after combined therapy, and pathological examination was performed after radical resection. (2) MRI and pathological examination of patients. Among the 37 patients, MRI before combined therapy showed 0, 0, 5, 24 and 8 cases in stage T0, T1, T2, T3 and T4, 10, 17 and 10 cases in stage N0, N1 and N2, 28 and 9 cases of positive and negative extramural vascular invasion (EMVI), 4 and 33 cases of positive and negative mesorectal fascia (MRF), respectively. MRI examination after combined therapy showed 15, 4, 7, 10 and 1 cases in stage T0, T1, T2, T3 and T4, 34, 2 and 1 cases in stage N0, N1 and N2, 9 and 28 cases of positive and negative EMVI, 1 and 36 cases of positive and negative MRF. There were 16, 13, 8 and 0 cases of tumor regression grading (TRG) 0, 1, 2 and 3, respectively. Postoperative pathological examination showed 18, 4, 3, 11, 1 cases in stage T0, T1, T2, T3, T4, 33, 3, 1 cases in stage N0, N1, N2, positive and negative EMVI and unknown data in 1, 35, 1 cases, positive and negative circumferential margin in 0 and 37 cases, grade 0, grade 1, grade 2, grade 3 of American Joint Committee on Cancer TRG in 18, 9, 8, 2 cases, respectively. Pathological complete response rate was 48.6%(18/37) and approximate pathological complete response rate was 24.3%(9/37). (3)Concordance analysis of MRI examination reading. The κ value of T staging and N staging on MRI before combined therapy was 0.839 (P<0.05) and 0.838 (P<0.05), respectively. The κ value of T staging and N staging on MRI after combined therapy was 0.531 (P<0.05) and 0.846 (P<0.05), respectively. The κ value of EMVI and MRF was 0.708 (P<0.05) and 0.680 (P<0.05) before combined therapy, and they were 0.561 (P<0.05) and 1.000 (P<0.05) after combined therapy, respectively. The κ value of TRG 3‑round reading for TRG was 0.448 (P<0.05). (4) Evaluation of MRI examination. ① MRI evaluation of T and N staging. The accuracy of MRI examination after combined therapy for distinguishing stage T0 was 75.7%28/37, 95% confidence interval (CI) as 62.2%-89.2%, the understaging rate was 8.1%(3/37, 95%CI as 0-18.9%), the overstaging rate was 16.2%(6/37, 95%CI as 5.4%-29.7%). The accuracy of MRI examination for distinguishing stage T0-T2 was 86.5%(32/37, 95%CI as 73.0%-97.3%), its understaging rate and overstaging rate were 8.1%(3/37, 95%CI as 0-18.9%) and 5.4% (2/37, 95%CI as 0-13.5%), respectively. The accuracy of MRI examination for distinguishing N staging was 91.9%(34/37, 95%CI was 81.1%-100.0%), its understaging rate and overstaging rate were 5.4%(2/37, 95%CI as 0-13.5%) and 2.7%(1/37, 95%CI as 0-8.1%), respectively. Among 18 patients in pathological stage T0, the overstaging rate of MRI was 33.3%(6/18). All the 4 patients in pathological stage T1 and 3 pati-ents in pathological stage T2 had correct diagnosis. There were 3 cases with understaging among 12 patients in pathological stage T3-T4. Among the 37 patients in pathological stage N0-N2, 34 cases had correct diagnosis, 1 case was overstaged as stage N1 due to a round mesorectal lymph node with short diameter as 6 mm, and 2 cases were diagnosed as stage N0 due to the small lymph nodes with the maximum short diameter as 3 mm. ② MRI evaluation of EMVI and MRF. The accuracy, sensitivity and negative predictive value of MRI for evaluating EMVI were 86.5%(32/37, 95%CI as 75.0%-97.2%), 100.0% and 100.0%, respectively, and the overestimation rate of EMVI was 13.9%(5/36, 95%CI as 2.8%-25.0%), and no underestimation occurred. Of 35 pathologically negative EMVI patients, a rate of 14.3%(5/35) of patients were positive on MRI. The main reason for overestaging was that thickened fibrous tissue outside the rectal wall was mistaken for vascular invasion. The accuracy of MRI for evaluating MRF was 97.3%(36/37, 95%CI as 91.9%-100.0%), and 1 case (1/37, 2.7%, 95%CI as 0-8.1%) was overestimated as positive MRF due to misdiagnosis of pararectal MRF lymph nodes. The negative predictive value of MRI for assessing MRF was 100.0%. ③ MRI evaluation of TRG. The accuracy, understaging and overstaging rates of MRI for evaluating pathological TRG 0 were 78.4%(29/37, 95%CI as 64.9%-91.9%), 8.1%(3/37, 95%CI as 0-18.9%), 13.5%(5/37, 95%CI as 5.4%-27.0%), respectively. The accuracy, understaging and overstaging rates of MRI for evaluating pathological TRG 0-1 were 89.2%(33/37, 95%CI as 78.4%-97.3%), 8.1%(3/37, 95%CI as 0-18.9%), 2.7%(1/37, 95%CI as 0-8.1%), respectively. Of the 18 patients with pathologic complete response, 5 cases were diagnosed as pathological TRG 1 and 13 cases as pathological TRG 0. One near‑pCR patient was assessed as pathological TRG 2. Two patients with pathological TRG 3 were incorrectly diagnosed on MRI.
    Conclusions Anti‑PD‑1 combined with neoadjuvant therapy can downstage the LARC pati-ents with MSS/pMMR. MRI is effective in predicting T staging, N staging, EMVI, MRF and TRG. However, overstaging should be prevented.

     

/

返回文章
返回